心臓アロ移植における亜鉛媒介によるアポトーシスの減少
M H Kown1, T Van der Steenhoven, F G Blankenberg
1Department of Cardiothoracic Surgery, Stanford University School of Medicine, Stanford, CA 94305-5247, USA.
Circulation
|November 18, 2000
まとめ
亜鉛塩化物 (ZnCl2) は,カスパース-3活性を阻害することによって,急性心臓アロ移植拒絶時のアポトーシスを効果的に減少させます. この研究は,アポトーシスの投与量依存的減少と,治療されたラットにおける移植の生存率の改善を示しています.
科学分野:
- 免疫学 免疫学とは
- 移植生物学 移植生物学について
- バイオケミストリー バイオケミストリー
背景:
- 心臓アロ移植の免疫媒介の急性拒絶にはアポトーシスが含まれます.
- 実験室内研究では,亜鉛がプロアポプトシス酵素カスパース-3を抑制することを示しています.
- この研究では,カスパース3依存アポトーシスをインビヴォでブロックする潜在的な治療薬として亜鉛塩化物 (ZnCl2) を調査しています.
研究 の 目的:
- 急性心臓アロインプラント拒絶時のアポトーシスの減少におけるZnCl2の有効性を評価する.
- ZnCl2の投与が移植の生存率に影響するかどうかを判断する.
- 心臓アロ移植におけるカスパース3活性に対するZnCl2の影響を評価する.
主な方法:
- ネズミモデルでの異種心臓移植 (PVGからACIまで).
- 異なる量のZnCl2 (1 mg/kg, 5 mg/kg) または塩素を投与されたラットに投与した.
- (99m) Tcラベル付アネキシンVイメージングは,アロ移植におけるアポトーシスを定量化します.
- 移植の生存時間とカスパース-3活性度の測定.
主要な成果:
- ZnCl2の治療は, (99m) TcアネキシンVの摂取量を量に依存して減少させ,アポトーシスの減少を示した.
- 移植後の生存期間は,対照群と比較して,ZnCl2で治療されたラットで著しく延長されました.
- アロ移植におけるカスパース3の活性度は,より高用量ZnCl2群で有意に低下した.
結論:
- ZnCl2は,急性心臓アロインプラント拒絶におけるアポトーシスを効果的に減少させます.
- 観察されたアポトーシスの減少は,カスパース-3の阻害によって媒介されます.
- ZnCl2は,心臓アロインプラント拒絶の管理に治療的可能性を示しています.
関連する概念動画
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
Imbalances in Cardiac Output
The heart's primary function is to pump blood throughout the body, maintaining a balance between blood sent out (cardiac output) and blood returning (venous return). If this balance is disrupted, it can result in congestive heart failure (CHF), a severe condition where the heart becomes an inefficient pump, leading to inadequate blood circulation.
CHF can occur due to the failure of either side of the heart. Left-side failure leads to pulmonary congestion—the right side continues to send blood...
CHF can occur due to the failure of either side of the heart. Left-side failure leads to pulmonary congestion—the right side continues to send blood...
Heart Failure VI: Adjunct Therapies
Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
Cardiomyopathy II: Dilated Cardiomyopathy
Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...
Cardiomyopathy III: Hypertrophic Cardiomyopathy
Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...
Cardiomyopathy V: Interprofessional Care
Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...


